…
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Adhera Therapeutics Inc is a small, development-stage biopharmaceutical company listed on the OTC Pink market with limited public disclosure about its pipeline. Long-term growth may depend on advancing product candidates, securing regulatory approvals and entering partnerships, which could appeal to investors seeking high-upside biotech exposure.
Material investment risks include absence of commercial products, substantial financing and dilution risk, clinical development setbacks, and very low trading liquidity that can impede exits.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -4.49M | -2.11M | -6.35M | -3.77M | -11.98M |
| Net income | -4.49M | 2.35M | -7.78M | -5.54M | -12.64M |
| Selling general administrative | 1.28M | 1.62M | 0.66M | 1.20M | 4.71M |
| Selling and marketing expenses | - | - | 0.02M | 0.84M | 5.26M |
| Gross profit | - | - | - | 0.03M | -0.16M |
| Reconciled depreciation | - | - | - | 0.02M | 0.08M |
| Ebit | - | -1.62M | -1.49M | -2.07M | -11.32M |
| Ebitda | - | -1.62M | -0.81M | -1.99M | -11.23M |
| Depreciation and amortization | - | 0.00M | 0.67M | 0.08M | 0.08M |
| Non operating income net other | - | - | - | 0.04M | - |
| Operating income | -1.28M | -1.62M | -0.67M | -2.04M | -11.32M |
| Other operating expenses | - | 1.62M | 0.67M | 2.04M | 10.45M |
| Interest expense | 3.19M | 3.15M | 1.43M | 1.77M | 0.66M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -4.00M | -3.15M | -1.43M | -1.77M | -0.66M |
| Non recurring | - | - | - | - | 1.12M |
| Income tax expense | - | -4.47M | 1.43M | 1.77M | 0.66M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.13M | 0.25M |
| Total operating expenses | 1.28M | 1.62M | 0.67M | 2.04M | 10.04M |
| Cost of revenue | - | - | - | 0.10M | 0.41M |
| Total other income expense net | 0.80M | -0.50M | -5.68M | -1.73M | -0.66M |
| Net income from continuing ops | -4.49M | -2.11M | -6.35M | -3.77M | -11.98M |
| Net income applicable to common shares | - | - | -8.40M | -5.31M | -13.48M |
| Preferred stock and other adjustments | - | - | - | 1.54M | 1.50M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 0.08M | 0.20M | 0.00M | 0.42M | 5.14M |
| Intangible assets | - | - | - | - | 0.39M |
| Other current assets | - | - | - | 0.37M | 0.16M |
| Total liab | 22.27M | 25.30M | 14.77M | 10.31M | 2.21M |
| Total stockholder equity | -22.19M | -25.11M | -14.77M | -9.89M | 2.93M |
| Other current liab | 6.39M | 13.17M | 4.09M | 2.56M | 1.06M |
| Common stock | - | 0.10M | 0.07M | 0.07M | 0.07M |
| Capital stock | 0.02M | 0.10M | 0.07M | 0.07M | 0.06M |
| Retained earnings | -55.75M | -53.02M | -44.61M | -39.33M | -25.85M |
| Good will | - | - | - | - | 0.00M |
| Cash | 0.03M | 0.08M | 0.00M | 0.05M | 3.92M |
| Total current liabilities | 22.27M | 25.30M | 14.77M | 10.31M | 2.21M |
| Net debt | 8.55M | 6.59M | 6.32M | 5.28M | - |
| Short term debt | - | - | 6.32M | 5.33M | - |
| Short long term debt | 8.59M | 6.66M | 6.32M | 5.33M | - |
| Property plant equipment | - | - | - | - | 0.07M |
| Total current assets | 0.08M | 0.20M | 0.00M | 0.42M | 4.68M |
| Net tangible assets | - | -25.11M | -14.77M | -9.89M | 2.54M |
| Net receivables | - | - | - | 0.00M | 0.05M |
| Inventory | - | - | - | 0.00M | 0.24M |
| Accounts payable | 2.40M | 2.31M | 8.46M | 1.40M | 0.29M |
| Common stock total equity | - | - | 0.07M | 0.07M | - |
| Retained earnings total equity | - | - | -44.61M | -39.33M | - |
| Non currrent assets other | - | - | - | 0.00M | 0.46M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.46M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | - | - | - | - | 0.00M |
| Change to liabilities | - | - | 0.09M | 1.03M | 0.94M |
| Net borrowings | - | - | 0.84M | 0.54M | -0.71M |
| Total cash from financing activities | 0.61M | 1.37M | 0.74M | 0.54M | 4.87M |
| Change to operating activities | - | - | -0.09M | 0.54M | -0.43M |
| Net income | -4.49M | -2.11M | -6.35M | -3.77M | -11.98M |
| Change in cash | -0.10M | -0.04M | 0.07M | -0.05M | -3.87M |
| Begin period cash flow | 0.13M | 0.08M | 0.00M | 0.05M | 3.92M |
| End period cash flow | 0.03M | 0.03M | 0.07M | 0.00M | 0.05M |
| Total cash from operating activities | -0.71M | -1.42M | -0.67M | -0.59M | -8.74M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | - | 1.81M | 0.40M | 0.40M | 0.08M |
| Dividends paid | - | 0.62M | 2.05M | 1.54M | 1.50M |
| Change to inventory | - | - | -0.12M | -0.01M | -0.24M |
| Change to account receivables | - | - | 0.12M | 0.04M | 0.02M |
| Sale purchase of stock | 0.00M | -0.00M | -0.74M | -0.54M | -0.10M |
| Other cashflows from financing activities | - | -0.35M | 2.79M | 2.08M | 6.38M |
| Change to netincome | - | - | 5.28M | 0.94M | 2.30M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | - | - | - | - | 0.02M |
| Cash flows other operating | - | - | - | 0.37M | -0.22M |
| Cash and cash equivalents changes | - | - | - | -0.05M | -3.87M |
| Change in working capital | 0.63M | 0.20M | 0.01M | 1.40M | 0.48M |
| Stock based compensation | - | - | 0.00M | 0.01M | 0.77M |
| Other non cash items | 3.94M | 0.50M | 5.28M | 1.77M | 0.68M |
| Free cash flow | -0.71M | -1.42M | -0.67M | -0.59M | -8.74M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATRX Adhera Therapeutics Inc |
- -% |
0.00 | - | - | 8.23 | - | 54.79 | 11.45 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
8000 Innovation Parkway, Baton Rouge, LA, United States, 70820
919 518 3748
2
| Name | Title | Year Born |
|---|---|---|
| Dr. Zahed Subhan B.S., BS, L.L.B., LLB (Law), M.B.A., M.S., MBA, MS | CEO, Chief Scientific Officer & Chairman | 1958 |
| Mr. Andrew Albert Kucharchuk M.B.A. | Vice Chairman, COO, Acting CFO & Chief Bus. Officer | 1981 |
| Mr. Andrew Albert Kucharchuk M.B.A. | Vice Chairman, COO, Acting CFO & Chief Business Officer | 1981 |
| Mr. Andrew Albert Kucharchuk M.B.A. | Vice Chairman, COO & Chief Business Officer | 1981 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.